Abstract:Introduction Amyloid-beta (Aβ) protein is a major component of the extracellular plaque found in the brains of individuals with Alzheimer's disease (AD). In this study, we investigated the effect of trans -resveratrol as an antagonist treatment for moderate to mild AD, as well as its safety and tolerability. Methods This was a case–control study that enrolled 30 selected patients who had been clinically diagnosed with moderate to mild AD. These patients were randomly divided into two groups, namely, a placebo group ( n = 15) and a trans -resveratrol group ( n = 15) who received 500 mg trans -resveratrol orally once daily for 52 weeks. Brain magnetic resonance imaging (MRI) examinations were performed on and cerebrospinal fluid (CSF) samples were obtained from all participants before (baseline) and after the study (52 weeks). Enzyme-linked immunosorbent assays were used to determine the levels of plasma Aβ40 and Aβ42 and CSF Aβ40 and Aβ42. Results The results showed that the changes over the study period in the levels of Aβ40 in the blood and CSF of the patients treated with trans -resveratrol were not statistically significant ( P > 0.05). In contrast, patients who received placebo showed a significant decrease in Aβ40 levels compared with that at the beginning of the study (CSF Aβ40: P = 0.024, plasma Aβ40: P = 0.036). Analysis of the images on the brain MRI scans revealed that the brain volume of the patients treated with trans -resveratrol was significantly reduced at 52 weeks ( P = 0.011) compared with that of patients in the placebo treatment group, Further analysis indicated that the level of matrix metallopeptidase 9 in the CSF of the patients treated with trans -resveratrol at 52 weeks decreased by 46% compared with that of patients in the placebo group ( P = 0.033). Conclusion These results indicate that trans -resveratrol has potential neuroprotective roles in the treatment of moderate to mild AD and that its mechanism may involve a reduction in the accumulation and toxicity of Aβ in the brain of patients, thereby reducing neuroinflammation. Trial Registration Chinese clinical trial registry: CTR20151780X.

The resveratrol trimer miyabenol C inhibits β-secretase activity and β-amyloid generation.

Resveratrol inhibits beta-amyloid oligomeric cytotoxicity but does not prevent oligomer formation.

Resveratrol Inhibits Β-Amyloid-induced Neuronal Apoptosis Through Regulation of SIRT1-ROCK1 Signaling Pathway.

Resveratrol Attenuates Oxidative Damage Through Activating Mitophagy in an in Vitro Model of Alzheimer's Disease.

The Recent Updates of Therapeutic Approaches Against Aβ for the Treatment of Alzheimer's Disease

Resveratrol inhibits oligomeric Aβ‑induced microglial activation via NADPH oxidase

P4‐687: SUBSTRATE BINDING INHIBITS Γ‐secretase CLEAVAGE OF AMYLOID PRECURSOR PROTEIN

Inhibition of Γ-Secretase Activity Reduces Aβ Production, Reduces Oxidative Stress, Increases Mitochondrial Activity and Leads to Reduced Vulnerability to Apoptosis: Implications for the Treatment of Alzheimer's Disease

Tenuigenin Treatment Decreases Secretion of the Alzheimer’s Disease Amyloid Β-Protein in Cultured Cells

Resveratrol Attenuates Aβ-Induced Early Hippocampal Neuron Excitability Impairment via Recovery of Function of Potassium Channels

Genipin Attenuates Tau Phosphorylation and Aβ Levels in Cellular Models of Alzheimer’s Disease

Tabersonine Inhibits Amyloid Fibril Formation and Cytotoxicity of Aβ(1–42)

Inhibition of Delta-Secretase Improves Cognitive Functions in Mouse Models of Alzheimer’s Disease

Neuroprotective Effect of Trans -Resveratrol in Mild to Moderate Alzheimer Disease: A Randomized, Double-Blind Trial

Resveratrol as a therapeutic agent for Alzheimer's disease.

Resveratrol Attenuates the Disruption of Lipid Metabolism Observed in APP/PS1 Mouse Brains and Cultured Primary Neurons Exposed to Aβ

Substrate Interaction Inhibits Γ-Secretase Production of Amyloid-Β Peptides.

Design, synthesis, and evaluation of multitarget-directed resveratrol derivatives for the treatment of Alzheimer's disease.

Resveratrol As A Therapeutic Agent for Alzheimer'S Disease

Ginsenoside Re Reduces Aβ Production by Activating PPARγ to Inhibit BACE1 in N2a/APP695 Cells.

The Binding of Resveratrol to Monomer and Fibril Amyloid Beta